DoH Policies screened during the period: 1 April 2024 – 30 June 2024
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- NICE Technology Appraisal TA956 - Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (PDF 513KB)
- NICE Technology Appraisal TA955 - Dupilumab for treating moderate to severe prurigo nodularis (PDF 514KB)
- NICE Technology Appraisal TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (review of TA613 and TA301) (PDF 563KB)
- NICE Technology Appraisal TA957 - Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (PDF 622KB)
- NICE Technology Appraisal TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and overtreatments (PDF 513KB)
- NICE Technology Appraisal TA959 - Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (PDF 510KB)
- NICE Technology Appraisal TA962 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (PDF 515KB)
- NICE Technology Appraisal TA963 - Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. (PDF 513KB)
- NICE Technology Appraisal TA964 - Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (PDF 513KB)
- NICE Clinical Guideline NG237 - Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management (partially updates and replaces CG191 (PDF 564KB)
- NICE Technology Appraisal TA967 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (partial review of TA540) (PDF 514KB)
- NICE Clinical Guideline NG239 - Vitamin B12 deficiency in over 16s: diagnosis and management (PDF 558KB)
- The Firefighters’ Pension Schemes and Compensation Scheme (Amendment) Regulations (Northern Ireland) 2024 - Survivors’ Benefit and Correction of the Public Service Pensions Revaluation Orders (NI) for 2021 and 2022. (PDF 548KB)
- NICE Technology Appraisal TA970 - Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (review of TA700) (PDF 511KB)
- Draft Foster Placement & Fostering Agencies Regulations (Northern Ireland) (PDF 631KB)
- NICE Technology Appraisal TA971 - Remdesivir and tixagevimab plus cilgavimab for treating COVID-19. (PDF 683KB)
- NICE Technology Appraisal TA973 - Atogepant for preventing migraine (PDF 511KB)
- NICE Clinical Guideline NG140 - Abortion care (PDF 517KB)
- NICE Clinical Guideline NG241 - Ovarian cancer: identifying and managing familial and genetic risk (PDF 565KB)
- NICE Technology Appraisal TA975 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (review of TA554) (PDF 514KB)
- NICE Technology Appraisal TA974 - Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (review of TA700). (PDF 513KB)
- NICE Technology Appraisal TA977 - Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (PDF 512KB)
- ‘Bereaved NI’ - Northern Ireland Bereavement Network website (PDF 533KB)
- NICE Public Health Guideline NG212 - Mental wellbeing at work (PDF 514KB)
- • Management of the prescribing of cow’s milk allergy formula in infants 12 months and over. (PDF 659KB)
- Safe and Effective Staffing (PDF 522KB)